Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:contrastsWith |
surgical aortic valve replacement
CoreValve System |
| gptkbp:enrollment |
high-risk patients
|
| gptkbp:focusesOn |
severe aortic stenosis
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:number |
NCT01240902
|
| gptkbp:period |
Phase III
|
| gptkbp:principalInvestigator |
gptkb:Michael_J._Reardon
David H. Adams |
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
all-cause mortality at 1 year
|
| gptkbp:sponsor |
gptkb:Medtronic
|
| gptkbp:startDate |
2011
|
| gptkbp:studies |
transcatheter aortic valve replacement
|
| gptkbp:bfsParent |
gptkb:CoreValve
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
CoreValve US Pivotal Trial
|